Tevogen Bio Holdings Inc.

Tevogen Inc. is a clinical-stage specialty immunotherapy company that develops off-the-shelf, precision T cell therapies for infectious diseases, cancers, and other disorders. Its pipeline includes TVGN 489, which has completed a Phase 1 trial in ambulatory high-risk adult COVID-19 patients and is in Phase 1 trials for acute SARS-CoV-2 patients with B-cell cancer immune suppression, other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, and Long COVID prevention and treatment. The company is also developing preclinical candidates: TVGN 920 for cervical cancer, TVGN 960 for oropharyngeal cancer, TVGN 601 for multiple sclerosis, TVGN 930 for Epstein-Barr virus associated lymphomas, and TVGN 116 for hepatitis B. It also offers an artificial intelligence platform for drug development. Tevogen Inc. was formerly known as Tevogen Bio Holdings Inc. and changed its name to Tevogen Inc. in July 2026. The company was incorporated in 2020 and is headquartered in Warren, New Jersey.